High Expression of DEPDC1 Promotes Malignant Phenotypes of Breast Cancer Cells and Predicts Poor Prognosis in Patients With Breast Cancer

Overview

Journal Front Oncol

Specialty Oncology

Date 2019 Apr 30

PMID 31032225

Citations 26

Authors

Huishan Zhao

Mingwei Yu

Laijian Sui

Benjiao Gong

Bo Zhou

Jian Chen

Zhaohua Gong

Cuifang Hao

Affiliations

Soon will be listed here.

Abstract

DEP domain containing 1 (DEPDC1) is a novel tumor-associated gene, which is aberrantly expressed in multiple types of cancer and involves in tumorigenesis and cancer progression. Here, we examined the functional involvement and underlying mechanism of DEPDC1 in breast cancer. In this study, the immunohistochemistry results demonstrated that DEPDC1 was high-expressed in breast cancer tissues compared with the paired adjacent normal breast tissues, and its tendency at protein level was consistent with mRNA level from TCGA data. Moreover, DEPDC1 mRNA level revealed the strongest association with poor prognosis and development in breast cancer. assays showed that DEPDC1 overexpression resulted in significant promotion of proliferation by regulating cell cycle in MCF-7 cells, whilst an opposite effect was found in the MDA-MB-231 cells with DEPDC1 deletion. Notably, further investigation indicated DEPDC1's ability of promoting breast cancer cells migration and invasion. In addition, we discovered that DEPDC1 caused hyper-activation of PI3K/AKT/mTOR signaling in breast cancer cells. Therefore, the increased DEPDC1 expression in breast cancer is correlated with disease progression and poor survival, which suggested that DEPDC1 might be a potential therapeutic target against this disease.

Citing Articles

Roles of DEPDC1 in various types of cancer (Review).

Liu D, Li H, Ouyang J Oncol Lett. 2024; 28(5):518.

PMID: 39296974 PMC: 11409430. DOI: 10.3892/ol.2024.14651.

DEPDC1 as a metabolic target regulates glycolysis in renal cell carcinoma through AKT/mTOR/HIF1α pathway.

Di S, Chen W, Yang W, Zhang X, Dong K, Tian Y Cell Death Dis. 2024; 15(7):533.

PMID: 39068164 PMC: 11283501. DOI: 10.1038/s41419-024-06913-1.

Wnt/β-Catenin Signaling Pathway in Pediatric Tumors: Implications for Diagnosis and Treatment.

Choudhary S, Singh M, Kashyap S, Seth R, Singh L Children (Basel). 2024; 11(6).

PMID: 38929279 PMC: 11201634. DOI: 10.3390/children11060700.

DEP domain containing 1 as a biomarker for poor prognosis in lung adenocarcinoma.

Li C, Zhu X Heliyon. 2024; 10(9):e30642.

PMID: 38765113 PMC: 11101781. DOI: 10.1016/j.heliyon.2024.e30642.

Targeting DEP domain containing 1 in anaplastic thyroid carcinoma: Implications for stemness regulation and malignant phenotype suppression.

Zhu C, Ke S, Li Y, Zhang W, Che Y, Zhang R Heliyon. 2024; 10(5):e27150.

PMID: 38449652 PMC: 10915564. DOI: 10.1016/j.heliyon.2024.e27150.

References

Kanehira M, Harada Y, Takata R, Shuin T, Miki T, Fujioka T . Involvement of upregulation of DEPDC1 (DEP domain containing 1) in bladder carcinogenesis. Oncogene. 2007; 26(44):6448-55. DOI: 10.1038/sj.onc.1210466. View

Harada Y, Kanehira M, Fujisawa Y, Takata R, Shuin T, Miki T . Cell-permeable peptide DEPDC1-ZNF224 interferes with transcriptional repression and oncogenicity in bladder cancer cells. Cancer Res. 2010; 70(14):5829-39. DOI: 10.1158/0008-5472.CAN-10-0255. View

Kretschmer C, Sterner-Kock A, Siedentopf F, Schoenegg W, Schlag P, Kemmner W . Identification of early molecular markers for breast cancer. Mol Cancer. 2011; 10(1):15. PMC: 3045364. DOI: 10.1186/1476-4598-10-15. View

Okayama H, Kohno T, Ishii Y, Shimada Y, Shiraishi K, Iwakawa R . Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas. Cancer Res. 2011; 72(1):100-11. DOI: 10.1158/0008-5472.CAN-11-1403. View

Vogel C, Marcotte E . Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat Rev Genet. 2012; 13(4):227-32. PMC: 3654667. DOI: 10.1038/nrg3185. View

Obara W, Ohsawa R, Kanehira M, Takata R, Tsunoda T, Yoshida K . Cancer peptide vaccine therapy developed from oncoantigens identified through genome-wide expression profile analysis for bladder cancer. Jpn J Clin Oncol. 2012; 42(7):591-600. DOI: 10.1093/jjco/hys069. View

Kassambara A, Schoenhals M, Moreaux J, Veyrune J, Reme T, Goldschmidt H . Inhibition of DEPDC1A, a bad prognostic marker in multiple myeloma, delays growth and induces mature plasma cell markers in malignant plasma cells. PLoS One. 2013; 8(4):e62752. PMC: 3640027. DOI: 10.1371/journal.pone.0062752. View

Colak D, Nofal A, AlBakheet A, Nirmal M, Jeprel H, Eldali A . Age-specific gene expression signatures for breast tumors and cross-species conserved potential cancer progression markers in young women. PLoS One. 2013; 8(5):e63204. PMC: 3660335. DOI: 10.1371/journal.pone.0063204. View

Sendoel A, Maida S, Zheng X, Teo Y, Stergiou L, Rossi C . DEPDC1/LET-99 participates in an evolutionarily conserved pathway for anti-tubulin drug-induced apoptosis. Nat Cell Biol. 2014; 16(8):812-20. DOI: 10.1038/ncb3010. View

10.

Yuan S, Liao W, Yang J, Huang G, Huang Z . DEP domain containing 1 is a novel diagnostic marker and prognostic predictor for hepatocellular carcinoma. Asian Pac J Cancer Prev. 2015; 15(24):10917-22. DOI: 10.7314/apjcp.2014.15.24.10917. View

11.

Tomczak K, Czerwinska P, Wiznerowicz M . The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (Pozn). 2015; 19(1A):A68-77. PMC: 4322527. DOI: 10.5114/wo.2014.47136. View

12.

Mi Y, Zhang C, Bu Y, Zhang Y, He L, Li H . DEPDC1 is a novel cell cycle related gene that regulates mitotic progression. BMB Rep. 2015; 48(7):413-8. PMC: 4577292. DOI: 10.5483/bmbrep.2015.48.7.036. View

13.

Conlon N, Howard J, Catalano J, Gallagher M, Tan L, Corben A . Breast Carcinoma in Young Women: No Evidence of Increasing Rates of Metastatic Breast Carcinoma in a Single Tertiary Center Review. Breast J. 2016; 22(3):287-92. PMC: 5558606. DOI: 10.1111/tbj.12575. View

14.

Conlon N, Sadri N, Corben A, Tan L . Acinic cell carcinoma of breast: morphologic and immunohistochemical review of a rare breast cancer subtype. Hum Pathol. 2016; 51:16-24. PMC: 5027139. DOI: 10.1016/j.humpath.2015.12.014. View

15.

Bianchini G, Balko J, Mayer I, Sanders M, Gianni L . Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016; 13(11):674-690. PMC: 5461122. DOI: 10.1038/nrclinonc.2016.66. View

16.

Zagelbaum N, Ward 2nd M, Okby N, Karpoff H . Invasive ductal carcinoma of the breast with osteoclast-like giant cells and clear cell features: a case report of a novel finding and review of the literature. World J Surg Oncol. 2016; 14(1):227. PMC: 5000466. DOI: 10.1186/s12957-016-0982-6. View

17.

Kikuchi R, Sampetrean O, Saya H, Yoshida K, Toda M . Functional analysis of the DEPDC1 oncoantigen in malignant glioma and brain tumor initiating cells. J Neurooncol. 2017; 133(2):297-307. DOI: 10.1007/s11060-017-2457-1. View

18.

Chen D, Ito S, Hyodo T, Asano-Inami E, Yuan H, Senga T . Phosphorylation of DEPDC1 at Ser110 is required to maintain centrosome organization during mitosis. Exp Cell Res. 2017; 358(2):101-110. DOI: 10.1016/j.yexcr.2017.06.005. View

19.

Huang L, Chen K, Cai Z, Chen F, Shen H, Zhao W . DEPDC1 promotes cell proliferation and tumor growth via activation of E2F signaling in prostate cancer. Biochem Biophys Res Commun. 2017; 490(3):707-712. DOI: 10.1016/j.bbrc.2017.06.105. View

20.

Jiang A, Zhao H, Liu X, Yu M, Chen J, Jiang W . Comparison of Different Muscle-Relaxant Anesthetics on Growth, Migration and Invasion of Gastric Cancer Cells. Anticancer Res. 2017; 37(8):4371-4378. DOI: 10.21873/anticanres.11831. View